Oncopeptides AB Stock OTC Markets
Stocks
ONPPF
SE0009414576
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 625M 65.57M 57M 53.05M 48.71M 91.98M 6.26B 93.41M 245M 3.12B 246M 241M 10.45B | P/E 2026 * |
-3.4x | P/E 2027 * | -6.46x |
|---|---|---|---|---|---|
| Enterprise Value | 670M 70.23M 61.05M 56.83M 52.17M 98.53M 6.7B 100M 263M 3.34B 264M 258M 11.19B | EV / Sales 2026 * |
4.74x | EV / Sales 2027 * | 2.83x |
| Free-Float |
90.95% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Oncopeptides AB
| 1 day | -55.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 46 | 2023-08-06 |
| Director of Finance/CFO | 52 | 2023-11-12 | |
Stefan Norin
CTO | Chief Tech/Sci/R&D Officer | 54 | 2023-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 2011-12-31 | |
| Director/Board Member | 63 | 2017-01-31 | |
Per Wold-Olsen
CHM | Chairman | 78 | 2018-05-16 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -55.83% | -67.28% | - | - | 65.57M | |
| +2.35% | +2.74% | +38.10% | +74.02% | 56.54B | |
| -1.13% | -6.71% | +25.39% | +61.93% | 53.6B | |
| -2.44% | +1.40% | -15.61% | -13.72% | 22.91B | |
| -2.85% | -7.78% | -9.28% | +352.92% | 21.37B | |
| +0.15% | +0.36% | +24.28% | -14.44% | 20.27B | |
| +0.38% | -2.33% | +31.79% | -29.17% | 17.56B | |
| -1.45% | -7.15% | +17.96% | +554.50% | 14.75B | |
| +3.41% | -6.61% | +162.81% | +287.77% | 13.53B | |
| -5.25% | -4.23% | +42.32% | +160.72% | 13.33B | |
| Average | -6.26% | -3.79% | +35.31% | +159.39% | 25.98B | |
| Weighted average by Cap. | -0.35% | -2.96% | +30.11% | +120.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 141M 14.82M 12.88M 11.99M 11.01M 20.78M 1.41B 21.11M 55.46M 704M 55.64M 54.42M 2.36B | 239M 25.1M 21.82M 20.31M 18.65M 35.22M 2.4B 35.76M 93.97M 1.19B 94.28M 92.21M 4B |
| Net income | -147M -15.4M -13.38M -12.46M -11.44M -21.6M -1.47B -21.93M -57.63M -732M -57.82M -56.55M -2.45B | -82.33M -8.63M -7.5M -6.98M -6.41M -12.11M -824M -12.3M -32.31M -410M -32.42M -31.71M -1.38B |
| Net Debt | 44.5M 4.67M 4.06M 3.78M 3.47M 6.55M 445M 6.65M 17.46M 222M 17.52M 17.14M 744M | 51.5M 5.4M 4.69M 4.37M 4.01M 7.58M 515M 7.69M 20.21M 257M 20.28M 19.83M 860M |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
